Intellia Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that uses CRISPR gene-editing technology to develop medicines for genetic diseases. Founded in 2014 with Nobel Prize-winning scientist Jennifer Doudna as a co-founder, it made history in 2021 by delivering the first-ever CRISPR edit inside a human body, targeting a protein that causes a rare heart condition. Its name blends "intelligence" with a biotech-style suffix.
Granted 156.4K · Sold 22.7K
Granted 9.2K
Granted 61.3K
Granted 46.1K · Sold 1.2K
Granted 9.2K
Granted 39.2K
Granted 9.9K
Granted 7.4K · Sold 607
Granted 17.3K
Granted 9.2K
Granted 9.2K
Granted 9.2K
Granted 9.2K
Granted 9.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leonard John MPresident and CEO, Director · 3 transactions | +12.5% | 1.21M | 156.4K | — | 22.7K |
| Cohen Fred EDirector · 1 transaction | +4.4% | 216.7K | 9.2K | — | — |
| Dulac Edward J IIIEVP, Chief Financial Officer · 1 transaction | +61.5% | 161.0K | 61.3K | — | — |
| Basta JamesEVP, General Counsel · 2 transactions | +54.4% | 156.8K | 46.1K | — | 1.2K |
| Chase William JDirector · 1 transaction | +6.8% | 143.9K | 9.2K | — | — |
| Schultes Birgit CEVP, Chief Scientific Officer · 1 transaction | +39.8% | 137.7K | 39.2K | — | — |
| Lebwohl DavidEVP, Chief Medical Officer · 1 transaction | +8.2% | 131.2K | 9.9K | — | — |
| Clark ElianaEVP, Chief Technical Officer · 2 transactions | +7.7% | 93.9K | 7.4K | — | 607 |
| Dube Michael PVP, Chief Accounting Officer · 1 transaction | +33% | 69.5K | 17.3K | — | — |
| Keresty GeorgiaDirector · 1 transaction | +28.9% | 41.1K | 9.2K | — | — |
| Bhanji MunaDirector · 1 transaction | +33.8% | 36.4K | 9.2K | — | — |
| Verwiel FrankDirector · 1 transaction | +35.5% | 35.1K | 9.2K | — | — |
| Goodman JesseDirector · 1 transaction | +37.8% | 33.6K | 9.2K | — | — |
| Goff BrianDirector · 1 transaction | +39.3% | 32.6K | 9.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -24.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.